Summary of efficacy (R/R cohorts and 1L cohort)
| . | R/R MDS . | 1L MDS . | |
|---|---|---|---|
| Cohort A (n = 11) . | Cohort B (n = 14) . | Cohort C (n = 21) . | |
| ORR (CR, PR, mCR, HI, mCR + HI), n (%) | 0 | 2 (14.3) | 13 (61.9) |
| HRR (CR, PR, HI, mCR + HI), n (%) | 0 | 2 (14.3) | 9 (42.9) |
| DOR, d (95% CI) | NE | 224.5 (84.0-365.0) | 577.0 (116.0-668.0) |
| Median time to AML progression, d (range) | 148 (39-271) | NE | 662.0 (1.0-662.0) |
| Median PFS, d | 138 | 240 | 309 |
| Median OS, d | 265 | 361 | 659 |
| . | R/R MDS . | 1L MDS . | |
|---|---|---|---|
| Cohort A (n = 11) . | Cohort B (n = 14) . | Cohort C (n = 21) . | |
| ORR (CR, PR, mCR, HI, mCR + HI), n (%) | 0 | 2 (14.3) | 13 (61.9) |
| HRR (CR, PR, HI, mCR + HI), n (%) | 0 | 2 (14.3) | 9 (42.9) |
| DOR, d (95% CI) | NE | 224.5 (84.0-365.0) | 577.0 (116.0-668.0) |
| Median time to AML progression, d (range) | 148 (39-271) | NE | 662.0 (1.0-662.0) |
| Median PFS, d | 138 | 240 | 309 |
| Median OS, d | 265 | 361 | 659 |
1L, frontline; HRR, hematologic response rate; NE, not estimable; PFS, progression-free survival.